Cancer prevention has fallen victim to the culture wars. Throughoutthe United States, state legislatures are scrambling to respondto the availability of Merck's human papillomavirus (HPV) vaccine,Gardasil, and to the likely introduction of GlaxoSmithKline'snot-yet-approved HPV vaccine, Cervarix, which have been shownto be effective in preventing infection with HPV strains thatcause about 70% of cases of cervical cancer. At the Centersfor Disease Control and Prevention (CDC), the Advisory Committeeon Immunization Practices (ACIP) has voted unanimously to recommendthat girls 11 and 12 years of age receive the vaccine, and theCDC has added Gardasil . . . [Full Text of this Article]
Source Information
Professor Charo is a professor of law and bioethics at the University of Wisconsin, Madison.
An interview with Professor Charo can be heard at www.nejm.org.
This article has been cited by other articles:
Outterson, K., Kesselheim, A. S.
(2008). Market-Based Licensing For HPV Vaccines In Developing Countries. Health Aff (Millwood)
27: 130-139
[Abstract][Full Text]
Lo, B.
(2007). Human papillomavirus vaccination programmes. BMJ
335: 357-358
[Full Text]
Fimbres, A., Barton, L. L.
(2007). How Effective Is the Quadrivalent HPV Vaccine at Preventing High-grade Cervical Lesions?. AAP Grand Rounds
18: 16-17
[Full Text]
Stange, K. C.
(2007). In This Issue: Clinical Diagnosis and Management. Ann Fam Med
5: 290-291
[Full Text]
Baden, L. R., Curfman, G. D., Morrissey, S., Drazen, J. M.
(2007). Human Papillomavirus Vaccine -- Opportunity and Challenge. NEJM
356: 1990-1991
[Full Text]
(2007). HPV Vaccination: Data at Last. JWatch General
2007: 1-1
[Full Text]